JP2013545738A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013545738A5 JP2013545738A5 JP2013537139A JP2013537139A JP2013545738A5 JP 2013545738 A5 JP2013545738 A5 JP 2013545738A5 JP 2013537139 A JP2013537139 A JP 2013537139A JP 2013537139 A JP2013537139 A JP 2013537139A JP 2013545738 A5 JP2013545738 A5 JP 2013545738A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- seq
- antibody
- light chain
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 87
- 239000000427 antigen Substances 0.000 claims 83
- 102000036639 antigens Human genes 0.000 claims 83
- 108091007433 antigens Proteins 0.000 claims 83
- 239000000203 mixture Substances 0.000 claims 46
- 102000008022 Proto-Oncogene Proteins c-met Human genes 0.000 claims 43
- 108010089836 Proto-Oncogene Proteins c-met Proteins 0.000 claims 43
- 239000012634 fragment Substances 0.000 claims 29
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims 23
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 claims 21
- 102100035361 Cerebellar degeneration-related protein 2 Human genes 0.000 claims 21
- 101000737793 Homo sapiens Cerebellar degeneration-related antigen 1 Proteins 0.000 claims 21
- 101000737796 Homo sapiens Cerebellar degeneration-related protein 2 Proteins 0.000 claims 21
- 238000006467 substitution reaction Methods 0.000 claims 17
- 102000005962 receptors Human genes 0.000 claims 10
- 108020003175 receptors Proteins 0.000 claims 10
- 230000004913 activation Effects 0.000 claims 8
- 210000004027 cell Anatomy 0.000 claims 7
- 102000009203 Sema domains Human genes 0.000 claims 6
- 108050000099 Sema domains Proteins 0.000 claims 6
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims 6
- 230000005888 antibody-dependent cellular phagocytosis Effects 0.000 claims 6
- 230000004540 complement-dependent cytotoxicity Effects 0.000 claims 5
- 230000001404 mediated effect Effects 0.000 claims 5
- 239000005557 antagonist Substances 0.000 claims 4
- 239000012636 effector Substances 0.000 claims 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- 102000004169 proteins and genes Human genes 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- VOUAQYXWVJDEQY-QENPJCQMSA-N 33017-11-7 Chemical group OC(=O)CC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)CCC1 VOUAQYXWVJDEQY-QENPJCQMSA-N 0.000 claims 2
- 239000000556 agonist Substances 0.000 claims 2
- 230000001419 dependent effect Effects 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 230000003042 antagnostic effect Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 230000003013 cytotoxicity Effects 0.000 claims 1
- 231100000135 cytotoxicity Toxicity 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40986610P | 2010-11-03 | 2010-11-03 | |
| US61/409,866 | 2010-11-03 | ||
| PCT/EP2011/069372 WO2012059562A1 (en) | 2010-11-03 | 2011-11-03 | C-met antibody combinations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013545738A JP2013545738A (ja) | 2013-12-26 |
| JP2013545738A5 true JP2013545738A5 (enExample) | 2014-12-18 |
Family
ID=44906140
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013537138A Active JP5857060B2 (ja) | 2010-11-03 | 2011-11-03 | 抗ｃ−Ｍｅｔ抗体 |
| JP2013537139A Pending JP2013545738A (ja) | 2010-11-03 | 2011-11-03 | ｃ−Ｍｅｔ抗体組合せ |
| JP2015177202A Pending JP2016034957A (ja) | 2010-11-03 | 2015-09-09 | 抗ｃ−Ｍｅｔ抗体 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013537138A Active JP5857060B2 (ja) | 2010-11-03 | 2011-11-03 | 抗ｃ−Ｍｅｔ抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015177202A Pending JP2016034957A (ja) | 2010-11-03 | 2015-09-09 | 抗ｃ−Ｍｅｔ抗体 |
Country Status (12)
| Country | Link |
|---|---|
| US (7) | US8637027B2 (enExample) |
| EP (3) | EP3165538A1 (enExample) |
| JP (3) | JP5857060B2 (enExample) |
| CN (2) | CN103764678A (enExample) |
| AU (3) | AU2011325098B2 (enExample) |
| BR (3) | BR122014027420A2 (enExample) |
| CA (2) | CA2816919A1 (enExample) |
| DK (1) | DK2635602T3 (enExample) |
| ES (1) | ES2594493T3 (enExample) |
| IL (2) | IL226113A0 (enExample) |
| RU (2) | RU2013125457A (enExample) |
| WO (2) | WO2012059562A1 (enExample) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8444976B2 (en) | 2008-07-02 | 2013-05-21 | Argen-X B.V. | Antigen binding polypeptides |
| EP2143441A1 (en) * | 2008-07-08 | 2010-01-13 | Pierre Fabre Medicament | Combination of a c-Met antagonist and an aminoheteroaryl compound for the treatment of cancer |
| EP3165538A1 (en) | 2010-11-03 | 2017-05-10 | Argen-X Nv | Anti c-met antibodies |
| KR20130036993A (ko) * | 2011-10-05 | 2013-04-15 | 삼성전자주식회사 | ｃ-Ｍｅｔ의 ＳＥＭＡ 도메인 내의 에피토프에 특이적으로 결합하는 항체 |
| ES2767135T3 (es) * | 2011-10-19 | 2020-06-16 | Novimmune Sa | Métodos para purificar anticuerpos |
| EP2773660A2 (en) * | 2011-11-03 | 2014-09-10 | Argen-X B.V. | Chimeric human-camel antigens and their use |
| US20130129718A1 (en) | 2011-11-21 | 2013-05-23 | Genentech, Inc. | Purification of anti-c-met antibodies |
| EP2785741A1 (en) * | 2011-12-02 | 2014-10-08 | Cancer Research Technology Limited | Antibodies against hgf - receptor and uses |
| US9670275B2 (en) | 2012-01-23 | 2017-06-06 | Ablynx N.V. | Sequences directed against hepatocyte growth factor (HGF) and polypeptides comprising the same for the treatment of cancers and/or tumors |
| US9931400B2 (en) | 2012-09-12 | 2018-04-03 | Samsung Electronics Co., Ltd. | Method of combination therapy for prevention or treatment of c-Met or angiogenesis factor induced diseases |
| US9168300B2 (en) | 2013-03-14 | 2015-10-27 | Oncomed Pharmaceuticals, Inc. | MET-binding agents and uses thereof |
| US9535055B2 (en) * | 2013-03-28 | 2017-01-03 | Samsung Electronics Co., Ltd. | Marker for determining effects of anti-c-Met antibody and method of determining effects of anti-c-Met antibody using the marker |
| EP2786765B1 (en) | 2013-04-01 | 2018-10-03 | Samsung Electronics Co., Ltd. | Composition for combination therapy comprising an anti-C-met antibody and a FGFR inhibitor |
| KR102139607B1 (ko) * | 2013-04-01 | 2020-07-30 | 삼성전자주식회사 | 항 c-Met 항체 및 FGFR 저해제를 포함하는 병용 투여용 약학 조성물 |
| US10214593B2 (en) | 2013-04-02 | 2019-02-26 | Samsung Electronics Co., Ltd. | Anti-idiotype antibody against anti-c-MET antibody |
| KR102060540B1 (ko) | 2013-04-03 | 2019-12-31 | 삼성전자주식회사 | 항 c-Met 항체 및 항 Ang2 항체를 포함하는 병용 투여용 약학 조성물 |
| US9994644B2 (en) | 2013-04-30 | 2018-06-12 | Agency For Science, Technology And Research | mAB 2 anti-Met antibody |
| KR102186363B1 (ko) * | 2013-09-06 | 2020-12-04 | 삼성전자주식회사 | c-Met 저해제 및 베타-카테닌 저해제를 포함하는 병용 투여용 약학 조성물 |
| KR102192591B1 (ko) * | 2013-09-09 | 2020-12-18 | 삼성전자주식회사 | c-Met 저해제 및 c-Myc 저해제를 포함하는 병용 투여용 약학 조성물 |
| EP3176269B1 (en) * | 2014-07-29 | 2020-12-02 | Wellmarker Bio Co., Ltd. | Inhibitors of met and igsf1 for treating cancer |
| IL250902B (en) * | 2014-09-16 | 2022-08-01 | Symphogen As | Anti-met antibodies and compositions |
| WO2016149265A1 (en) * | 2015-03-16 | 2016-09-22 | Kolltan Pharmaceuticals, Inc. | Anti-met antibodies and methods of use thereof |
| GB201611123D0 (en) * | 2016-06-27 | 2016-08-10 | Euremab Srl | Anti met antibodiesand uses thereof |
| CN118005799A (zh) * | 2016-09-23 | 2024-05-10 | 马伦戈治疗公司 | 包含λ轻链和κ轻链的多特异性抗体分子 |
| TWI782930B (zh) | 2016-11-16 | 2022-11-11 | 美商再生元醫藥公司 | 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法 |
| MX2019014316A (es) * | 2017-05-30 | 2020-01-27 | Chong Kun Dang Pharmaceutical Corp | Un nuevo anticuerpo anti-c-met y uso del mismo. |
| WO2018221969A1 (en) * | 2017-05-30 | 2018-12-06 | Chong Kun Dang Pharmaceutical Corp. | A novel anti-c-met antibody and use thereof |
| CA3070100A1 (en) | 2017-07-17 | 2019-01-24 | Janssen Biotech, Inc. | Antigen binding regions against fibronectin type iii domains and methods of using the same |
| CN109771642B (zh) | 2017-11-13 | 2022-09-20 | 同济大学苏州研究院 | c-MET激动型抗体及其用途 |
| MY205933A (en) * | 2018-09-27 | 2024-11-21 | Celgene Corp | Sirp-alpha binding proteins and methods of use thereof |
| US11591390B2 (en) | 2018-09-27 | 2023-02-28 | Celgene Corporation | SIRP-α binding proteins and methods of use thereof |
| KR20220063185A (ko) | 2019-09-16 | 2022-05-17 | 리제너론 파마슈티칼스 인코포레이티드 | 면역-pet 영상화를 위한 방사성 표지된 met 결합 단백질 |
| MX2023011929A (es) | 2021-04-08 | 2023-10-23 | Byondis Bv | Anticuerpos anti-c-met y conjugados de anticuerpo-farmaco. |
| JP2024536722A (ja) * | 2021-09-03 | 2024-10-08 | ジーオー セラピューティクス，インコーポレイテッド | 抗グリコｃｍｅｔ抗体およびその使用 |
| TW202500584A (zh) | 2023-05-19 | 2025-01-01 | 法商施維雅藥廠 | 抗met抗體、抗體-藥物結合物、組合物及其用途 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
| US5648273A (en) | 1989-12-27 | 1997-07-15 | The United States Of America, As Represented By The Department Of Health And Human Services | Hepatic growth factor receptor is the MET proto-oncogene |
| EP0662130B1 (en) | 1992-09-18 | 1997-11-26 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | A method of producing hepatocyte growth factor and a cell line |
| US5686292A (en) | 1995-06-02 | 1997-11-11 | Genentech, Inc. | Hepatocyte growth factor receptor antagonist antibodies and uses thereof |
| US6214344B1 (en) | 1995-06-02 | 2001-04-10 | Genetech, Inc. | Hepatocyte growth factor receptor antagonists and uses thereof |
| DE69739856D1 (de) | 1996-07-03 | 2010-06-02 | Genentech Inc | Agonisten für den rezeptor des hepatozyten-wachstumsfaktors und deren anwendungen |
| ITMI20031127A1 (it) | 2003-06-05 | 2004-12-06 | Uni Degli Studi Del Piemont E Orientale Am | Anticorpi anti-hgf-r e loro uso |
| CN101614745A (zh) * | 2003-06-06 | 2009-12-30 | 健泰科生物技术公司 | 调节HGFβ链和C-MET的相互作用 |
| HN2004000285A (es) | 2003-08-04 | 2006-04-27 | Pfizer Prod Inc | ANTICUERPOS DIRIGIDOS A c-MET |
| KR100556660B1 (ko) * | 2003-11-11 | 2006-03-10 | 국립암센터 | Ｈｇｆ의 중화가능 에피토프 및 이에 결합하는 중화 항체 |
| CN1922208A (zh) * | 2003-12-11 | 2007-02-28 | 健泰科生物技术公司 | 用于抑制c－met二聚化及活化的方法和组合物 |
| RU2398777C2 (ru) | 2004-08-05 | 2010-09-10 | Дженентек, Инк. | ГУМАНИЗИРОВАННЫЕ АНТАГОНИСТЫ, НАПРАВЛЕННЫЕ ПРОТИВ c-met |
| US20090068179A1 (en) | 2005-11-16 | 2009-03-12 | Fariba Nayeri | Methods for Inhibiting Carcinogenesis and/or Metastasis in an Individual with Endogenous C-Met Ligands and Inhibitors |
| KR101429297B1 (ko) | 2006-02-06 | 2014-08-12 | 메테레시스 트랜스레이셔날 리서치 에스.에이. | 종양 치료를 위한 항-Ｍｅｔ 단클론 항체, 이의 단편과벡터 및 상응하는 산물 |
| MX2008012485A (es) | 2006-03-30 | 2008-10-10 | Novartis Ag | Composiciones y metodos de uso para anticuerpos de c-met. |
| FR2906533B1 (fr) | 2006-09-28 | 2013-02-22 | Pf Medicament | Procede de generation d'anticorps actifs contre un antigene de resistance,anticorps obtenus par ledit procede et leurs utilisations |
| EP2014681A1 (en) * | 2007-07-12 | 2009-01-14 | Pierre Fabre Medicament | Novel antibodies inhibiting c-met dimerization, and uses thereof |
| JPWO2009011426A1 (ja) | 2007-07-19 | 2010-09-24 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | γ−セクレターゼの新規基質ｃ−Ｍｅｔを利用したスクリーニング方法 |
| US7892770B2 (en) | 2007-08-24 | 2011-02-22 | Van Andel Research Institute | Monoclonal antibody which binds cMet (HGFR) in formalin-fixed and paraffin-embedded tissues and related methods |
| IL198545A0 (en) | 2008-05-14 | 2011-07-31 | Metheresis Translational Res Sa | High affinity binding site of hgfr and methods for identification of antagonists thereof |
| US8455623B2 (en) | 2008-05-21 | 2013-06-04 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for diagnosing and treating cancer |
| AU2008356942A1 (en) | 2008-05-28 | 2009-12-03 | U-Protein Express B.V. | Method for the production of proteins or protein fragments |
| GB2461546B (en) | 2008-07-02 | 2010-07-07 | Argen X Bv | Antigen binding polypeptides |
| WO2010005965A1 (en) | 2008-07-08 | 2010-01-14 | Aronchick Craig A | Colonic purgative formulations and methods of using the same |
| PA8849001A1 (es) * | 2008-11-21 | 2010-06-28 | Lilly Co Eli | Anticuerpos de c-met |
| AR074439A1 (es) * | 2008-12-02 | 2011-01-19 | Pf Medicament | Anticuerpo anti-cmet (receptor c-met) |
| US8545839B2 (en) | 2008-12-02 | 2013-10-01 | Pierre Fabre Medicament | Anti-c-Met antibody |
| EP3165538A1 (en) | 2010-11-03 | 2017-05-10 | Argen-X Nv | Anti c-met antibodies |
-
2011
- 2011-11-03 EP EP16187257.7A patent/EP3165538A1/en not_active Withdrawn
- 2011-11-03 ES ES11778618.6T patent/ES2594493T3/es active Active
- 2011-11-03 BR BR122014027420-3A patent/BR122014027420A2/pt not_active Application Discontinuation
- 2011-11-03 WO PCT/EP2011/069372 patent/WO2012059562A1/en not_active Ceased
- 2011-11-03 EP EP11778618.6A patent/EP2635602B1/en active Active
- 2011-11-03 WO PCT/EP2011/069369 patent/WO2012059561A1/en not_active Ceased
- 2011-11-03 BR BR112013010687A patent/BR112013010687A2/pt not_active IP Right Cessation
- 2011-11-03 CN CN201180063338.6A patent/CN103764678A/zh active Pending
- 2011-11-03 AU AU2011325098A patent/AU2011325098B2/en not_active Ceased
- 2011-11-03 JP JP2013537138A patent/JP5857060B2/ja active Active
- 2011-11-03 BR BR112013010688-3A patent/BR112013010688B1/pt active IP Right Grant
- 2011-11-03 CA CA2816919A patent/CA2816919A1/en not_active Abandoned
- 2011-11-03 US US13/288,566 patent/US8637027B2/en active Active
- 2011-11-03 US US13/288,587 patent/US9688773B2/en active Active
- 2011-11-03 DK DK11778618.6T patent/DK2635602T3/en active
- 2011-11-03 AU AU2011325097A patent/AU2011325097B2/en active Active
- 2011-11-03 CN CN201180052993.1A patent/CN103562223B/zh active Active
- 2011-11-03 EP EP11778887.7A patent/EP2635603B1/en active Active
- 2011-11-03 JP JP2013537139A patent/JP2013545738A/ja active Pending
- 2011-11-03 CA CA2816745A patent/CA2816745C/en active Active
- 2011-11-03 RU RU2013125457/10A patent/RU2013125457A/ru unknown
- 2011-11-03 RU RU2013125459A patent/RU2608644C2/ru active
-
2013
- 2013-05-02 IL IL226113A patent/IL226113A0/en unknown
- 2013-05-02 IL IL226112A patent/IL226112B/en active IP Right Grant
- 2013-12-06 US US14/098,849 patent/US9884917B2/en active Active
-
2015
- 2015-02-17 US US14/624,193 patent/US9688774B2/en active Active
- 2015-02-17 US US14/624,216 patent/US9631027B2/en active Active
- 2015-08-07 AU AU2015210420A patent/AU2015210420B2/en active Active
- 2015-09-09 JP JP2015177202A patent/JP2016034957A/ja active Pending
-
2017
- 2017-05-16 US US15/596,890 patent/US20170349667A1/en not_active Abandoned
- 2017-12-26 US US15/854,312 patent/US10676535B2/en active Active